Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
1.100
+0.030 (2.80%)
At close: May 13, 2025, 4:00 PM
1.040
-0.060 (-5.45%)
Pre-market: May 14, 2025, 7:22 AM EDT
Silo Pharma Employees
Silo Pharma had 3 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$24,034
Profits / Employee
-$1,540,883
Market Cap
4.93M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 1 | 50.00% |
| Dec 31, 2021 | 2 | 1 | 100.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SILO News
- 13 days ago - Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study - GlobeNewsWire
- 15 days ago - Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug - GlobeNewsWire
- 6 weeks ago - Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - GlobeNewsWire
- 2 months ago - Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment - GlobeNewsWire
- 3 months ago - Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - GlobeNewsWire
- 3 months ago - Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia - GlobeNewsWire
- 3 months ago - Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - GlobeNewsWire
- 4 months ago - Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - GlobeNewsWire